Clinical Cancer Research Grants Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Inoue, H.
Right arrow Articles by Mori, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inoue, H.
Right arrow Articles by Mori, M.
Clinical Cancer Research Vol. 8, 3475-3479, November 2002
© 2002 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Prognostic Score of Gastric Cancer Determined by cDNA Microarray1

Hiroshi Inoue, Ayumi Matsuyama, Koshi Mimori, Hiroaki Ueo and Masaki Mori2

Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838 [H. I., A. M., K. M., M. M.], and Department of Surgery, Oita Prefectural Hospital, Oita 870-0855 [H. U.], Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: To estimate gastric cancer patients’ prognosis more comprehensively,we tried to develop a prognostic scoring system using a cDNA microarray.

Experimental Design: RNA was extracted from tumor/normal paired samples of 43 patients with gastric cancer, and cDNA microarray hybridization was performed.

Results: We selected 78 genes that were differentially expressed between aggressive and nonaggressive groups with respect to five conventional pathological factors. Next, we determined a coefficient for each gene. Thereafter a prognostic score was calculated by summing-up the value for each gene. It ranged from -47 to 201 with a median of 114. There were two peaks in its distribution. Ten of 11 patients who were alive with no evidence of recurrence >5 years after the operation showed a score of <100 points, whereas all 19 patients who died of disease showed >100 points. In 13 patients who were alive but the follow-up time was <5 years, 2 of the 3 patients with >100 points revealed recurrent disease during the follow-up.

Conclusions: These findings demonstrate that such a system with cDNA microarray can contribute to the comprehensive analysis of malignant behavior of the tumor and may provide accurate information on prognosis.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Gastric cancer is one of the ten most frequent cancers in the world, and it is the second most common in Japan. Recent improvements in diagnostic tools and methods have facilitated detection of early gastric cancer; however, there still exist patients whose tumor is advanced at the time of diagnosis (1) . Prognosis depends on the stage of disease. Patients with stage I disease have a good prognosis, and those with stage IV disease show a very poor prognosis (1) . It is difficult to predict the prognosis of each patient with stage II or III disease because these stages include patients with either a good or a poor outcome. In other words, these stages include high-grade and low-grade malignant tumors. To differentiate the malignant potential appropriately, many efforts have been made to select prognostic markers.

Several interesting molecules have been reported with respect to the prognosis of gastric cancer patients. These include cell cycle regulation factors such as p27 or proliferating cell nuclear antigen, matrix proteinases, cell adhesion molecules such as E-cadherin, autocrine motility factors, angiogenic factors, growth factors, oncogenes, tumor suppressor genes such as p53, and several others (1, 2, 3, 4, 5, 6) . The expression of these molecules has been studied at the protein level by immunohistochemistry or at the RNA level by molecular methodologies such as Northern blot or reverse transcription-PCR. The interpretation of the immunohistochemical results is often difficult and sometimes different between investigators. On the other hand, it is more quantitative based on Northern blot or reverse transcription-PCR analysis. However, these methods cannot evaluate many genes at once. In addition, only one or a few selected molecules will not define the whole characteristics of a tumor. Thus, it has been recommended to study the malignant potential of a tumor from the viewpoint of the total expression profile of many genes.

Recent excellent advances in the cDNA microarray technique that can investigate gene expression systematically enable us to visualize gene expression profiles in human tumors (7, 8, 9) . This technique can show another interesting possibility; it may be equivalent to multiple competitive Northern blot analyses to evaluate the tumor:normal ratio of many genes simultaneously. The purpose of this study was to establish a prognostic scoring system for gastric cancer using cDNA microarray. Our strategy was to: (a) select the differentially expressed genes between two different groups for each of the five conventional pathological factors; (b) determine a coefficient of expression for each gene; and (c) calculate the prognostic score. Our prognostic scoring system was revealed to be very useful in the determination of an individual’s prognosis.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Tissue Specimens.
Gastric cancer tissues, along with corresponding normal gastric tissues from the same patient, were excised during surgery from 43 patients from 1994 to 1998. All grossly dissected tissue specimens were frozen in liquid nitrogen and kept at -90°C. Informed consent was obtained from the patients. Clinical and pathological descriptions were made according to the criteria outlined by the Japanese Research Society for Gastric Cancer. The stage of disease was as follows: 11 stage I, 10 stage II, 15 stage III, and 7 stage IV. Five of the stage IV patients showed liver metastasis and two showed peritoneal dissemination at surgery, and a simple gastrectomy was performed. The interval of follow-up after operation ranged from 93 days to 7 years 11 months with a mean of 4 years and 7 months.

RNA Isolation and cDNA Microarray.
The total RNA was extracted from the specimens as described previously (10) . Poly(A)+ mRNA was prepared from total RNA using oligotex TM-MAG mRNA purification kit (TaKaRa Shuzo Co., Ltd., Shiga, Japan). The fluorescently labeled cDNA probes were prepared as described. One-µg aliquots of RNA from cancer tissue and normal corresponding tissue were labeled using the RNA Fluorescence Labeling Core Kit (TaKaRa Shuzo Co., Ltd.) with Cy3-dUTP and Cy5-dUTP (Amersham), respectively, in each paired case.

We used the commercially available cDNA microarray (IntelliGene Human Cancer chip; TaKaRa Shuzo Co., Ltd.) that contains 425 selected known human genes that are considered to be cancer related. These include oncogenes, tumor suppressor genes, growth factors, apoptosis-related genes, matrix proteinase genes, angiogenesis-related genes, drug-resistant genes, and so on. The internal control genes included 14 genes such as ß-actin, ATP synthase, or glyceraldehyde-3-phosphate dehydrogenase. Labeled probes were mixed with hybridization solution (6x SSC, 0.2% SDS, 5x Denhardt’s solution, and 0.1 mg/ml denatured salmon sperm DNA). After hybridization for 14 h at 42°C, the slides were twice washed in 2x SSC and 0.1% SDS for 30 min at 55°C, washed in 2x SSC and 0.1% SDS for 5 min at 65°C, and washed in 0.05x SSC for 5 min at room temperature. The slides were scanned using the Affymetrix 418 (Affymetrix).

Data Analysis.
The signal intensity of hybridization was evaluated photometrically by the ImaGene computer program (BioDiscovery) and normalized to the averaged signals of housekeeping genes. A cutoff value for each expression level was automatically calculated according to the background fluctuation. The fluctuation can be estimated as the variance of the log ratio of Cy3:Cy5 minus the variance of the log ratio of Cy3:Cy5 of highly expressed genes.

We selected five conventional prognostic factors (6 , 11) and divided the cases into two groups for each factor as shown in Table 1Citation . The average expression intensity of each gene was calculated in each group and compared between the two groups. Then we picked up the differentially expressed genes with a significant difference that was defined by the Student’s t test as mentioned below. The representative selected genes related to the depth of invasion and lymph node metastasis are shown in Table 2Citation . The frequency of pick-up of each gene was evaluated as a coefficient. This means that if the gene was selected as differentially in all five prognostic factors, its coefficient was evaluated as five. If it was picked up in relation to three prognostic factors, its coefficient was three. If the gene expression was inversely correlated with the malignant potential, a minus point was given in this case.


View this table:
[in this window]
[in a new window]

  		Table 1 Pathological factors

 

View this table:
[in this window]
[in a new window]

  		Table 2 Genes related to pathological factors

 
Statistical Analysis.
The average expression intensity of each gene was compared between the two groups for each of the five pathological factors, and the statistical difference was evaluated by Student’s t test.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
The average expression intensity of each gene was calculated in each group and compared between the two groups. Table 2Citation shows the selected genes that were differentially expressed with a significant difference between the two groups with respect to depth of tumor invasion (Table 2A)Citation and lymph node metastasis (Table 2B)Citation . Similarly, the differentially expressed genes were selected with respect to tumor size, histological growth pattern, and liver metastasis (data not shown).

Table 3Citation shows a coefficient for each gene ranging from plus 5 to minus 3. Interestingly, 347 of 425 evaluated genes were not differentially expressed between the two groups in any factor, and a coefficient was therefore 0. There was a significantly different expression in the remaining 78 genes between the two groups. Four genes were regarded as plus 5 because they appeared in all of the five factors; the next eight genes were regarded as plus 4 because they appeared in four factors. Similarly, 19 genes were scored as plus 3, 9 genes were plus 2, 20 genes were plus 1, 15 genes were minus 1, and 3 genes were minus 3. There was no gene scored as minus 2. To calculate the prognostic score using the 78 differentially expressed genes, the following formula was considered:

X means the log value of the expression ratio (Cy3:Cy5) for gene Xn. Y means a coefficient for gene Xn.


View this table:
[in this window]
[in a new window]

  		Table 3 Coefficient and genes related to malignancy

 
Fig. 1ACitation shows the distribution of the prognostic score in all 43 patients. The score ranged from -47 to 201 with a median of 114 points. There were two peaks around 50 and 130 points. The cutoff point for the prediction of the clinical outcome of the patients was selected as 100, arbitrarily based on the observed distribution of scores.



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. A, distribution of prognostic scores. The score ranged from -47 to 201 with a median of 114. Note the two peaks around 50 and 130 points. B, correlation between the prognostic score, stage of disease, and prognosis. Group A included patients who were alive with no evidence of recurrent disease >5 years after the operation, group B included patients who were alive but followed <5 years after the operation, and group C included patients who died of recurrence of their disease after operation.

 
Twenty patients had <100 points, and 23 patients had >100 points. Fig. 1BCitation shows the correlation between the prognostic score, stage of disease, and prognosis. The patients were divided into three groups. Group A included patients who were alive with no evidence of recurrent disease >5 years after operation, group B included patients who were alive but followed <5 years after operation, and group C included patients who died of recurrence of their disease after operation. Very interestingly, the prognostic scores of 10 of 11 patients in group A were <100 points, whereas those of all 19 patients in group C were >100 points. One stage I patient in group C died of liver metastasis, and the tumor showed the rare histology of hepatoid carcinoma that is known to produce {alpha}-fetoprotein and have a very poor prognosis (12) . Group B included 3 patients with >100 points and 10 with <100 points. Two of the 3 with >100 points showed recurrent disease; one stage II patient recurred in the paraaortic lymph nodes 3 years after operation, and the other stage III patient recurred in the liver 2.5 years after operation. None of the 10 patients with <100 points showed recurrent disease at the time of this writing.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
cDNA microarray is a powerful tool to monitor the complete transcriptional profile of hundreds to ten thousands of genes at once (7, 8, 9) . This technology has a strong impact not only on the basic biology of genetic information but also on clinical practice, and it is anticipated to produce more accurate disease diagnosis and more appropriate therapy. For example, Golub et al. (7) reported that acute myeloid leukemia and acute lymphoblastic leukemia could be classified by DNA microarray without previous knowledge of these classes. Alizadeh et al. (8) reported that the molecular classification of diffuse large B-cell lymphomas by DNA microarray could identify previously undetected and clinically significant subtypes. Regarding hepatocellular carcinoma, Okabe et al. (9) demonstrated that DNA microarray could differentiate hepatitis B-related carcinomas from hepatitis C-related ones. These studies demonstrate that the gene expression pattern as determined by DNA microarray is useful for differential diagnosis that has been difficult in routine histopathological examinations.

Our study demonstrates another useful application of cDNA microarray in clinical care. It has been difficult to predict the recurrence, metastasis, or prognosis of the individual gastric cancer patient, especially those with an intermediate stage, by the conventional staging system. Thus, it is desirable to estimate the grade of malignancy of the tumor as a score. Our study demonstrates that it is possible to do so by cDNA microarray. The prognostic score in this case demonstrated that patients whose score was >100 points showed a poor prognosis, whereas those whose score was <100 points showed a good prognosis. In addition, this scoring system was able to evaluate a patient who showed an unexpected outcome; one patient with stage I disease died of liver metastasis 37 months after operation. The score of this patient was 137, indicating a poor prognosis, although his stage of disease was early. As shown in Fig. 1BCitation , the prognostic scoring system could differentiate high-risk patients in an intermediate stage of II or III. Two of three patients in group B (Fig. 1B)Citation showed recurrent disease, and the tumors of these patients showed a score of >100. These patients were difficult to identify using the conventional staging system.

The strategy for our scoring system was: (a) to select the differentially expressed genes between two different groups for each of the five conventional pathological factors; (b) to determine a coefficient for each gene; and (c) to calculate the prognostic score. The methods described here may be considered tentative and may be further refined. Variables include which conventional pathologic factors should be selected and what the most suitable method to determine a coefficient for each selected gene is. These problems will be resolved, and the most suitable method or analysis will be optimized by further studies in the near future.

The DNA chip used in this study contained 425 cancer-related genes that have been reported in the literature. Our study demonstrated that ~80% of these genes were not differentially expressed between aggressive and nonaggressive groups of gastric cancer. This means that not a large number of genes appear to participate in determining the grade of malignancy. Microdissection of exclusively tumor elements could, however, modify this conclusion. There were four genes that were selected in all five pathological factors. Of these, three genes such as matrix metalloproteinase-7 (13) , secreted protein, acidic, cysteine-rich (osteonectin) (14) , and transforming growth factor-ß3 (15) have been reported to be correlated with tumor progression or metastasis in several cancers including gastric cancer. Especially we have demonstrated that matrix metalloproteinase-7 is a good indicator of aggressive behavior of the tumor (13 , 16 , 17) , and this study confirmed our hypothesis. The molecules that are known to correlate with tumor progression or metastasis, such as fibronectin precursor, carcinoembryonic antigen-related cell adhesion molecule 6, IGF binding protein 3, or proliferating cell nuclear antigen were selected in four factors. On the other hand, thrombospondin 2 is an angiostatic factor reported to be suppressed in highly metastatic cancers; its expression was inversely correlated with tumor progression in colon or lung cancers (18 , 19) . Thus, the selection of thrombospondin 2 in this study of gastric cancer needs further study. However, recently, Lee et al. (20) reported similar results to those of our study in that it was overexpressed in gastric cancer compared with normal gastric tissue.

In conclusion, this study demonstrates that the prognosis of individual gastric cancer patients can be predicted by cDNA microarray technique. Such analysis will be important to both patients and their doctors in terms of life planning and treatment planning, respectively.


   ACKNOWLEDGMENTS
 
We thank the pertinent collaboration for Yoshie Yoshikawa, Jyunichi Mineno, Hiroyuki Mukai, Kiyozo Asada, and Ikunoshin Kato (Biotechnology Research Laboratories, Takara Shuzo Co., Ltd., Kusatsu, Japan). All of the microarray slides were made by the company and were provided for us with a cooperation.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by the Grant-in-Aid for Scientific Research on Priority Areas of Cancer (12215116, 11671251, 12218227), the Grant-in-Aid for Scientific Research (B) (12557100, 12470241) and (C) (12213101, 12671232, 12670166), and the Grant-in-Aid for Exploratory Research (13877188), the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work was also supported by the Uehara Memorial Foundation, Naito Foundation, Casio Science Promotion Foundation, Foundation for Promotion of Cancer Research in Japan, and Sagawa Foundation for Promotion of Cancer Research. Back

2 To whom requests for reprints should be addressed, at Department of Surgery, Medical Institute of Bioregulation, Kyushu university, 4546 Tsurumibaru, Beppu 874-0838, Japan. Back

Received 12/26/01; revised 7/15/02; accepted 7/16/02.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Akoh J. A., Macintyre I. M. C. Improving survival in gastric cancer—review of 5-year survival rates in English language publications from 1970. Br. J. Surg., 79: 293-299, 1992.[Medline]
  2. Stadtlander C. T. K. H., Waterbor J. W. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis (Lond.), 20: 2195-2207, 1999.[Abstract/Free Full Text]
  3. Mori M., Mimori K., Shiraishi T., Fujie T., Baba K., Kusumoto H., Haraguchi M., Ueo H., Akiyoshi T. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int. J. Cancer, 74: 316-321, 1997.[CrossRef][Medline]
  4. Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K., Akiyoshi T. p27 expression and gastric carcinoma. Nat. Med., 3: 593-593, 1997.[CrossRef][Medline]
  5. Mori M., Kakeji Y., Adachi Y., Moriguchi S., Maehara Y., Sugimachi K., Jessup J. M., Chen L. B., Steele G. D. The prognostic significance of proliferating cell nuclear antigen in clinical gastric cancer. Surgery, 113: 683-690, 1993.[Medline]
  6. Allgayer H., Heiss M. M., Schildberg F. W. Prognostic factors in gastric cancer. Br. J. Surg., 84: 1651-1664, 1997.[CrossRef][Medline]
  7. Golub T. R., Slonim D. K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J. P., Coller H., Loh M. L., Downing J. R., Caligiuri M. A., Bloomfield C. D., Lander E. S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (Wash. DC), 286: 531-537, 1999.[Abstract/Free Full Text]
  8. Alizadeh A. A., Eisen M. B., Davis R. E., Ma C., Lossos I. S., Rosenwald A., Boldrick J. C., Sabet H., Tran T., Yu X., Powell J. I., Yang L., Marti G. E., Moore T., Hudson J., Jr., Lu L., Lewis D. B., Tibshirani R., Sherlock G., Chan W. C., Greiner T. C., Weisenburger D. D., Armitage J. O., Warnke R., Staudt L. M., et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (Lond.), 403: 503-511, 2000.[CrossRef][Medline]
  9. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., Tsunoda T., Furukawa Y., Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res., 61: 2129-2137, 2000.[Abstract/Free Full Text]
  10. Mori M., Barnard G. F., Staniunas R. J., Jessup J. M., Steele G. D., Chen L. B. Prothymosin-{alpha} mRNA expression correlates with that of c-myc in human colon cancer. Oncogene, 8: 2821-2826, 1993.[Medline]
  11. Mori M., Sugimachi K. Clinicopathologic studies of gastric carcinoma. Semin. Surg. Oncol., 6: 19-27, 1990.[Medline]
  12. Chang Y. C., Nagasue N., Abe S., Kohno H., Kumar D. D., Nakamura T. {alpha}-fetoprotein producing early gastric cancer with liver metastasis—report of 3 cases. Gut, 32: 542-545, 1991.[Abstract/Free Full Text]
  13. Honda M., Mori M., Ueo H., Sugimachi K., Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut, 39: 444-448, 1996.[Abstract/Free Full Text]
  14. Thomas R., True L. D., Bassuk J. A., Lange P. H., Vessella R. L. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin. Cancer Res., 6: 1140-1149, 2000.[Abstract/Free Full Text]
  15. Li C. G., Wang J. M., Wilson P. B., Kumar P., Levine E., Hunter R. D., Kumar S. Role of transforming growth factor ß3 in lymphatic metastasis in breast cancer. Int. J. Cancer, 79: 455-459, 1998.[CrossRef][Medline]
  16. Mori M., Barnard G. F., Mimori K., Ueo H., Akiyoshi T., Sugimachi K. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer (Phila.), 75: 1516-1519, 1995.[CrossRef][Medline]
  17. Yamashita K., Mori M., Shiraishi T., Shibuta K., Sugimachi K. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin. Cancer Res., 6: 1169-1174, 2000.[Abstract/Free Full Text]
  18. Tokunaga T., Nakamura M., Oshika Y., Abe Y., Ozeki Y., Fukushima Y., Hatanaka H., Sadahiro S., Kijima H., Tsuchida T., Yamazaki H., Tamaoki N., Ueyama Y. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br. J. Cancer, 79: 354-359, 1999.[CrossRef][Medline]
  19. Oshika Y., Masuda K., Tokunaga T., Hatanaka H., Kamiya T., Abe Y., Ozeki Y., Kijima H., Yamazaki H., Tamaoki N., Ueyama Y., Nakamura M. Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin. Cancer Res., 4: 1785-1788, 1998.[Abstract]
  20. Lee J. H., Koh J. T., Shin B. A., Ahn K. Y., Roh J. H., Kim Y. J., Kim K. K. Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer. Int. J. Oncol., 18: 355-361, 2001.[Medline]



This article has been cited by other articles:


Home page
 Physiol. GenomicsHome page
B. J. Capoccia, W. J. Huh, and J. C. Mills
How form follows functional genomics: gene expression profiling gastric epithelial cells with a particular discourse on the parietal cell
Physiol Genomics, April 10, 2009; 37(2): 67 - 78.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
P. Qiu, Z. J. Wang, K. J. R. Liu, Z.-Z. Hu, and C. H. Wu
Dependence network modeling for biomarker identification
Bioinformatics, January 15, 2007; 23(2): 198 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. J. Tsai, R. Herrera-Goepfert, R. J. Tibshirani, S. Yang, A. Mohar, J. Guarner, and J. Parsonnet
Changes of Gene Expression in Gastric Preneoplasia following Helicobacter pylori Eradication Therapy.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 272 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-M. Kim, H.-Y. Sohn, S. Y. Yoon, J.-H. Oh, J. O. Yang, J. H. Kim, K. S. Song, S.-M. Rho, H. S. Yoo, Y. S. Kim, et al.
Identification of Gastric Cancer-Related Genes Using a cDNA Microarray Containing Novel Expressed Sequence Tags Expressed in Gastric Cancer Cells
Clin. Cancer Res., January 15, 2005; 11(2): 473 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. H. Yang, M. Y. Seo, H. J. Jeong, H.-C. Jeung, J. Shin, S. C. Kim, S. H. Noh, H. C. Chung, and S. Y. Rha
Gene Copy Number Change Events at Chromosome 20 and Their Association with Recurrence in Gastric Cancer Patients
Clin. Cancer Res., January 15, 2005; 11(2): 612 - 620.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. I. Meireles, E. B. Cristo, A. F. Carvalho, R. Hirata Jr., A. Pelosof, L. I. Gomes, W. K. Martins, M. D. Begnami, C. Zitron, A. L. Montagnini, et al.
Molecular Classifiers for Gastric Cancer and Nonmalignant Diseases of the Gastric Mucosa
Cancer Res., February 15, 2004; 64(4): 1255 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Boussioutas, H. Li, J. Liu, P. Waring, S. Lade, A. J. Holloway, D. Taupin, K. Gorringe, I. Haviv, P. V. Desmond, et al.
Distinctive Patterns of Gene Expression in Premalignant Gastric Mucosa and Gastric Cancer
Cancer Res., May 15, 2003; 63(10): 2569 - 2577.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Inoue, H.
Right arrow Articles by Mori, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inoue, H.
Right arrow Articles by Mori, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online